In vitro effects of omeprazole in combination with antifungal compounds against Malassezia pachydermatis. [PDF]
Vet Med Sci, 2023 Background Fungal and yeast infections, including those caused by Malassezia spp., are becoming increasingly difficult to treat, likely due to the occurrence of drug resistance. Objectives This study aimed to evaluate the antifungal effects of omeprazole
Shin J, Bae S.
europepmc +2 more sources
Invasive Malassezia pachydermatis Infection in an 8-Year-Old Child on Lipid Parenteral Nutrition. [PDF]
Case Rep Infect Dis, 2022 Invasive disease due to Malassezia pachydermatis infection is uncommon but increasingly recognized in children, especially neonates on parenteral nutrition or immunocompromised children.
Teoh Z, Mortensen J, Schaffzin JK.
europepmc +2 more sources
In Vitro Biofilm Formation by Malassezia pachydermatis Isolates and Its Susceptibility to Azole Antifungals. [PDF]
J Fungi (Basel), 2022 The yeast Malassezia pachydermatis, an opportunistic pathogen that inhabits the skin of various domestic and wild animals, is capable of producing a biofilm that plays an important role in antifungal resistance. The aim of this research study was to find
Čonková E +3 more
europepmc +2 more sources
In vitro antifungal activity of cold atmospheric microwave plasma and synergistic activity against Malassezia pachydermatis when combined with chlorhexidine gluconate. [PDF]
Vet Med Sci, 2022 Background The antifungal efficacy of cold atmospheric microwave plasma (CAMP) against Malassezia pachydermatis has not been to be evaluated. Objective To examine the antifungal effects of CAMP against M.
Lee TH +4 more
europepmc +2 more sources
Galleria mellonella as a Novelty in vivo Model of Host-Pathogen Interaction for Malassezia furfur CBS 1878 and Malassezia pachydermatis CBS 1879. [PDF]
Front Cell Infect Microbiol, 2020 Malassezia furfur and Malassezia pachydermatis are lipophilic and lipid dependent yeasts, associated with the skin microbiota in humans and domestic animals, respectively.
Torres M +5 more
europepmc +2 more sources
Azole resistance of Malassezia pachydermatis causing treatment failure in a dog. [PDF]
Med Mycol Case Rep, 2019 A 5-year-old neutered female toy Poodle chronically treated with systemic and topical azoles to control recurrent Malassezia dermatitis/otitis was presented because of the loss of treatment efficacy.
Angileri M +3 more
europepmc +2 more sources
Azole susceptibility ofMalassezia pachydermatisandMalassezia furfurand tentative epidemiological cut-off values [PDF]
Medical Mycology, 2015 This study aims to determine the minimal inhibitory concentration (MIC) distribution and the epidemiological cut-off values (ECVs) of Malassezia pachydermatis and Malassezia furfur isolates for fluconazole (FLZ), itraconazole (ITZ), posaconazole (POS ...
Claudia Cafarchia +2 more
exaly +3 more sources
Antifungal Efficacy of Selected Plant Essential Oils Against Clinical Canine Isolates <i>Malassezia pachydermatis</i>. [PDF]
MicroorganismsMalassezia pachydermatis, an important opportunistic secondary pathogen, is often associated with atopic dermatitis or otitis externa in dogs. Recent studies indicate an increase in resistance of this yeast to commonly used antifungal agents.
Čonková E, Váczi P, Malinovská Z.
europepmc +2 more sources
Prevalence of <i>Malassezia pachydermatis</i> yeasts in clinical infections in dogs: A single-center retrospective study at the University Veterinary Hospital, Stara Zagora, Bulgaria (2019-2023). [PDF]
Open Vet JBackground: Malassezia yeasts are part of the resident microbiota of canine skin and ear canal. The compromised immunity of animals, changes in environmental factors, and antibacterial treatment often result in their proliferation and subsequent ...
Dinkova V, Rusenova N.
europepmc +2 more sources
Shared occurrence of <i>Malassezia</i> spp. in dogs and their owners. [PDF]
One HealthMalassezia spp. are commensal yeasts inhabiting the skin of humans and animals; however, some species may cause dermatological disorders or bloodstream infections, especially in immunocompromised patients.
Miglianti M +7 more
europepmc +2 more sources